Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity

British Journal of Clinical Pharmacology

Volumn 55, Issue 2, 2003, Pages 158-165

  Alfirevic, Ana ^a   Stalford, Anne C ^a   Vilar, F Javier ^a,b   Wilkins, Ed G L ^b   Park, B Kevin ^a   Pirmohamed, Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Adverse drug reactions; HIV; Hypersensitivity; NAT2; Polymorphism; Sulphamethoxazole

Indexed keywords

ACYLTRANSFERASE; COTRIMOXAZOLE; DAPSONE;

ACETYLATOR PHENOTYPE; ADULT; ALLELE; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG ACETYLATION; DRUG HYPERSENSITIVITY; ERYTHEMA; EXON; FEVER; GENE DISCORDANCE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; METHODOLOGY; NAT2 GENE; NAUSEA; PNEUMOCYSTOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUBLICATION; RASH; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE HOMOLOGY; STEVENS JOHNSON SYNDROME; VOMITING;

ACETYLATION; ADULT; DRUG HYPERSENSITIVITY; GENOTYPE; HIV INFECTIONS; HUMANS; MIDDLE AGED; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SULFAMETHOXAZOLE;

EID: 0037329148     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01754.x     Document Type: Article

References (40)

1. Anonymous. Co-trimoxazole use restricted. Drug Ther Bull 1995; 33: 92-93.
2. Schneider MME, Nielsen TL, Nelsing S et al. Efficacy and toxicity of 2 doses of trimethoprim-sulphamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human-immunodeficiency-virus. J Infect Dis 1995; 171: 1632-1636.
3. Carr A, Penny R, Cooper DA. Efficacy and safety of rechallenge with low-dose trimetoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients. AIDS 1993; 7: 65-71.
4. Jaffe HS, Abrams DI, Ammann AJ, Lewis BJ, Golden JA. Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet 1983; 2: 1109-1111.
5. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15 438 consecutive inpatients, 1975 to 1982. J Am Med Assoc 1986; 256: 3358-3363.
6. Rieder MJ, Uetrecht JP, Shear NH, Cannon M, Miller M, Spielberg SP. Diagnosis of sulphonamide hypersensitivity reactions by in-vitro 'rechallenge' with hydroxylamine metabolites. Ann Intern Med 1989; 110: 286-289.
7. Cribb AE, Miller M, Leeder JS, Hill J, Spielberg SP. Reactions of the nitroso and hydroxylamine metabolites of sulphamethoxazole with reduced glutathione: implications for idiosyncratic toxicity. Drug Met Dispos 1991; 19: 900-906.
8. Carr A, Gross AS, Hoskins JM, Penny R, Cooper DA. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients. AIDS 1994; 8: 333-337.
9. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991; 49: 13-17.
10. Wolkenstein P, Carriere V, Charue D et al. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995; 5: 255-258.
11. Zielinska E, Niewiarowski W, Bodalski J. The aryamine N-acetyltransfease (NAT2) polymorphism and the risk of adverse reactions to co-trimoxazole in children. Eur J Clin Pharmacol 1998; 54: 779-785.
12. Lee BL, Wong D, Benowitz NL, Sullam PM. Altered patterns of drug-metabolism in patients with acquired-immunodeficiency syndrome. Clin Pharmacol Ther 1993; 53: 529-535.
13. Kaufmann GR, Wenk M, Taeschner W et al. N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1996; 60: 62-67.
14. Delomenie C, Grant DM, Mathelier-Fusade P et al. N-acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients. Br J Clin Pharmacol 1994; 38: 581.
15. Pirmohamed M, Alfirevic A, Vilar J et al. Association analysis of drug metabolising enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacogenetics 2000; 10: 705-713.
16. O'Neill WM, Drobitch RK, MacArthur RD et al. Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype. Pharmacogenetics 2000; 10: 171-182.
17. Blum M, Demierre A, Grant DM, Hein M, Meyer UA. Molecular mechanisln of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 1991; 88: 5237-5241.
18. Ilett KF, Chiswell GM, Spargo RM, Platt E, Minchin RF. Acetylation phenotype and genotype in Aboriginal leprosy patients from north-west region of Western Australia. Pharmacogenetics 1993; 3: 264-269.
19. Coleman MD, Scott AK, Breckenridge AM, Park BK. The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. Br J Clin Pharmacol 1990; 30: 761-767.
20. Hickman D, Sim E. N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem Pharmacol 1991; 42: 1007-1014.
21. Hickman D, Risch A, Camilleri JP, Sim E. Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants. Pharmacogenetics 1992; 2: 217-226.
22. Bell DA, Taylor JA, Butler MA et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993; 14: 1689-1692.
23. Fretland AJ, Leff MA, Doll MA, Hein DW. Functional characterisation of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics 2001; 11: 207-215.
24. Cascorbi I, Brockmoller J, Bauer S, Reum T, Roots I. NAT2*12A (803A→G) codes for rapid arylamine N-acetylation in humans. Pharmacogenetics 1996; 6: 257-259.
25. Wolkenstein P, Loriot M-A, Aracting S, Cabelguenne A, Beaune P, Chosidow O. Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS. Pharmacogenetics 2000; 10: 821-828.
26. Navin TR, Beard CB, Huang L et al. Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P. carinii pneumonia in patients with HIV-1: a prospective study. Lancet 2001; 358: 545-549.
27. Gill HJ, Maggs JL, Madden S, Pirmohamed M, Park BK. The effect of fluconazole and ketoconazole on the metabolism of sulphamethoxazole. Br J Clin Pharmacol 1996; 42: 347-353.
28. Cribb AE, Lee BL, Trepanier LA, Spielberg SP. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev 1999; 15: 9-50.
29. Cribb AE, Nakamura H, Grant DM, Miller MA, Spielberg SP. Role of polymorphic and monomorphic human arylamine N-acetytransferases in determining sulfamethoxazole metabolism. Biochem Pharmacol 1993; 45: 1277-1282.
30. Park BK, Pirmohamed M, Kitteringham NR. The role of drug disposition in drug hypersensitivity: a chemical, molecular and clinical perspective. Chem Res Toxicol 1998; 11: 969-988.
31. Nakamura H, Uetrecht J, Cribb AE et al. In vitro formation, disposition and toxicity of N-acetoxy-sulphamethoxazole, a potential mediator of sulphamethoxazole toxicity. JPET 1995; 274: 1099-1104.
32. O'Neill WM, Gilfix BM, DiGirolamo A, Tsoukas CM, Wainer IW. N-acetylation among HIV-positive patients and patients with AIDS. When is fast, fast and slow, slow? Clin Pharmacol Ther 1997; 62: 261-271.
33. Cascorbi I, Dracoulis N, Brockmoller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995; 57: 581-592.
34. Price Evans DA. N-acetyltransferase. Pharmac Ther 1989; 42: 157-234.
35. Gross M, Kruisselbrink T, Anderson K et al. Distribution and concordance of N-acetylatransferase genotype and phenotype in an American population. Cancer Epidemiol, Biomarkers Prevention 1999; 8: 683-692.
36. Hein DW, Grant DM, Sim E. Arylamine N-acetyltransferase (EC2.3.1.5). Nomenclature 2001. URL: http://www.louisville.edu/medschool/pharmacology/NAT.html
37. Zuidema J, Hilbers-Modderman ESM, Merkus FWHM. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 1986; 11: 299-315.
38. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 1984; 17: 459-464.
39. Bluhm RE, Adedoyin A, McCarver DG, Branch RA. Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors. Clin Pharmacol Ther 1999; 65: 598-605.
40. Meisel P, Arndt D, Scheuch E, Klebingat KJ, Siegmund W. Prediction of metabolic activity from genotype: the gene-dose effect of N-acetyltransferase. Ther Drug Monit 2001; 23: 9-14.